113 related articles for article (PubMed ID: 29325762)
1. Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis.
Thabit AK; Monogue ML; Newman JV; Nicolau DP
Int J Antimicrob Agents; 2018 May; 51(5):727-732. PubMed ID: 29325762
[TBL] [Abstract][Full Text] [Related]
2.
Zhao M; Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416552
[TBL] [Abstract][Full Text] [Related]
3. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.
Zhanel GG; Cheung D; Adam H; Zelenitsky S; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty A; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2016 Apr; 76(5):567-88. PubMed ID: 26863149
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms.
Monogue ML; Thabit AK; Hamada Y; Nicolau DP
Antimicrob Agents Chemother; 2016 Aug; 60(8):5001-5. PubMed ID: 27353265
[TBL] [Abstract][Full Text] [Related]
5.
Zhao M; Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987156
[TBL] [Abstract][Full Text] [Related]
6. Eravacycline for the treatment of intra-abdominal infections.
Bassetti M; Righi E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1575-84. PubMed ID: 25251475
[TBL] [Abstract][Full Text] [Related]
7. Eravacycline, a newly approved fluorocycline.
Lee YR; Burton CE
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1787-1794. PubMed ID: 31175478
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.
Petraitis V; Petraitiene R; Maung BBW; Khan F; Alisauskaite I; Olesky M; Newman J; Mutlib A; Niu X; Satlin M; Singh RS; Derendorf H; Walsh TJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941646
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.
Zhang Y; Lin X; Bush K
J Antibiot (Tokyo); 2016 Aug; 69(8):600-4. PubMed ID: 27353166
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.
Zhanel GG; Baxter MR; Adam HJ; Sutcliffe J; Karlowsky JA
Diagn Microbiol Infect Dis; 2018 May; 91(1):55-62. PubMed ID: 29338931
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
Andes D; Craig WA
Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
[TBL] [Abstract][Full Text] [Related]
12.
Abdelraouf K; Stainton SM; Nicolau DP
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061165
[TBL] [Abstract][Full Text] [Related]
13. Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo.
Thabit AK; Monogue ML; Nicolau DP
Antimicrob Agents Chemother; 2016 Aug; 60(8):5072-5. PubMed ID: 27353264
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline.
Newman JV; Zhou J; Izmailyan S; Tsai L
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150464
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic target assessment and prediction of clinically effective dosing regimen of TP0586532, a novel non-hydroxamate LpxC inhibitor, using a murine lung infection model.
Fujita K; Takata I; Yoshida I; Honma Y; Okumura H; Otake K; Takashima H; Sugiyama H
J Infect Chemother; 2022 May; 28(5):635-642. PubMed ID: 35131156
[TBL] [Abstract][Full Text] [Related]
16. Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications.
Huang PY; Hsu CK; Tang HJ; Lai CC
Expert Rev Anti Infect Ther; 2024 Jun; 22(6):387-398. PubMed ID: 38703093
[TBL] [Abstract][Full Text] [Related]
17. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
Bhalodi AA; Crandon JL; Williams G; Nicolau DP
Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of the novel monobactam LYS228 in a neutropenic murine thigh model of infection.
Growcott EJ; Cariaga TA; Morris L; Zang X; Lopez S; Ansaldi DA; Gold J; Gamboa L; Roth T; Simmons RL; Osborne CS
J Antimicrob Chemother; 2019 Jan; 74(1):108-116. PubMed ID: 30325447
[TBL] [Abstract][Full Text] [Related]
19. Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
Stearne LE; Goessens WH; Mouton JW; Gyssens IC
Antimicrob Agents Chemother; 2007 Oct; 51(10):3605-11. PubMed ID: 17646416
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
